Bradley & Co Private Wealth Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Bradley & Co Private Wealth Management’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$14.5K	Hold	27	–	–	0.01%	131
2026 Q1	$14.1K	Hold	27	–	–	0.01%	126
2025 Q4	$15.7K	Hold	27	–	–	0.01%	119
2025 Q3	$12.4K	Hold	27	–	–	0.01%	121
2025 Q2	$8.17K	Hold	27	–	–	0.01%	128
2025 Q1	$8.94K	Hold	27	–	–	0.01%	125
2024 Q4	$8.33K	Buy	+27	New	+$7.59K	0.01%	123
2024 Q2	$30.8K	Hold	110	–	–	0.02%	82
2024 Q1	$29.4K	Hold	110	–	–	0.02%	87
2023 Q4	$25.5K	Hold	110	–	–	0.02%	88
2023 Q3	$16.1K	Hold	110	–	–	0.02%	106
2023 Q2	$25.4K	Hold	110	–	–	0.03%	85
2023 Q1	$26.6K	Buy	110 +83	+307%	+$22.6K	0.03%	85
2022 Q4	$7.84K	Hold	27	–	–	0.01%	121
2022 Q3	$2K	Hold	27	–	–	﹤0.01%	169
2022 Q2	$2K	Hold	27	–	–	﹤0.01%	173
2022 Q1	$3K	Hold	27	–	–	﹤0.01%	140
2021 Q4	$2K	Hold	27	–	–	﹤0.01%	150
2021 Q3	$2K	Hold	27	–	–	﹤0.01%	151
2021 Q2	$3K	Hold	27	–	–	﹤0.01%	154
2021 Q1	$3K	Buy	+27	New	+$3.15K	﹤0.01%	156

Other funds holding MDGL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Bradley & Co Private Wealth Management's MDGL Position: Q2 2026 in Review

Bradley & Co Private Wealth Management held its Madrigal Pharmaceuticals (MDGL) position steady in Q2 2026 at 27 shares worth $14.5K. The position accounts for 0.01% of the portfolio, ranked #131.

Bradley & Co Private Wealth Management first reported a position in MDGL in Q1 2021 and has held it in 21 quarters since. The position peaked at $30.8K in Q2 2024. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

Bradley & Co Private Wealth Management held 27 shares of Madrigal Pharmaceuticals worth $14.5K as of Q2 2026.
Bradley & Co Private Wealth Management left its Madrigal Pharmaceuticals share count unchanged in Q2 2026.
Madrigal Pharmaceuticals made up 0.01% of Bradley & Co Private Wealth Management's portfolio in Q2 2026, its #131 holding.
Bradley & Co Private Wealth Management first reported a position in Madrigal Pharmaceuticals in Q1 2021 and has held it in 21 quarters since.
Bradley & Co Private Wealth Management's Madrigal Pharmaceuticals position peaked at $30.8K in Q2 2024.
414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Bradley & Co Private Wealth Management's 13F filing for Q2 2026, filed 10 Aug 2026.